Impact of ketogenic diet therapy on growth in children with epilepsy

Serena Lu1, Helena Champion2, Nicole Mills2

  • 1UCL, London, United Kingdom.

Epilepsy Research
|January 12, 2023
PubMed

Insights

Ketogenic diet therapy (KDT) can impact linear growth in children with epilepsy, with effects most pronounced in younger, non-ambulatory individuals on classical KDT. However, catch-up growth is observed after discontinuing the diet.

Area of Science:

  • Pediatric Neurology
  • Nutritional Science
  • Epilepsy Management

Background:

  • Ketogenic diet therapy (KDT) is a recognized treatment for drug-resistant epilepsy in children.
  • Evidence regarding KDT's effect on pediatric growth remains conflicting.
  • This study investigates KDT's impact on linear growth and weight in UK children.

Purpose of the Study:

  • To assess the effects of KDT on linear growth and weight in children with epilepsy.
  • To identify clinical or demographic factors associated with growth changes during KDT.
  • To provide data for informed discussions about KDT's potential growth implications.

Main Methods:

  • Retrospective review of medical records from 3 UK epilepsy centers.
  • Analysis of height and weight z-scores at baseline, during KDT (1-8 years), and 1-year post-diet.
  • Statistical analysis using Wilcoxon Signed Rank, Mann-Whitney, Kruskal-Wallis, and Spearman's Rank correlation tests.

Main Results:

  • Significant decrease in median height z-score observed at 1, 2, and 3 years on KDT.
  • No significant height or weight z-score changes 1 year after discontinuing KDT.
  • Greater height z-score reduction noted in non-ambulatory children, those on classical KDT, and younger children.
  • Weight z-score decreased significantly at 4 and 6 years on diet in a subset of patients.

Conclusions:

  • KDT can adversely affect linear growth in children, particularly in the initial 3 years.
  • Catch-up growth occurs after KDT discontinuation.
  • Non-ambulatory status, younger age, and classical KDT may increase growth vulnerability.
  • Close monitoring and discussion of potential short-term growth impacts are crucial for families considering KDT.
Abstract

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
240
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
110
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
67
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
240
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
509
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
397